# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023. XOM...
Leerink Partners analyst Jason Zhuang initiates coverage on XOMA (NASDAQ:XOMA) with a Outperform rating and announces Price ...
HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.
As previously announced on February 16, 2024, XOMA Corporation (("XOMA" or the "Company", NASDAQ:XOMA) entered ...
HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA (NASDAQ:XOMA) with a Buy and maintains $74 price target.